2.3x EV to TTM Revenue.

These five stocks all have very high quality businesses that I want to buy more shares in, if only the market would offer a slightly better price.

At one point I was up almost 100%, but now I’m down almost 50%. And new information about management has come to light.

It’s always sad when the thesis breaks but it is best to acknowledge it.

These 4 small cap stocks are relatively unknown, despite all making an operating profit, and growing those profits considerably.

These three little businesses are all valued under $15 million, but seem to have potential to be worth more than that.

What are the best ASX dividend stocks to buy? I don’t know, but when I look for dividend shares I prefer to buy growing dividend stocks.

The market responded to Energy One’s acquisition of a competitor by bidding up the Energy One share price.

The market likes Damstra’s acquisition of TIKS, pushing the Damstra share price up 10% at the time of writing. But arguably, it does increase risk as well as potential rewards.

Austalian Clinical Labs shares are expected to rise as the company has announced yet another earnings upgrade due to high covid testing.

Volpara is on a mission to increase early detection of breast cancer.

The recent approval of Eisai’s Aduhelm has got the market’s attention, because it translates into higher profits for Cogstate.

Some stocks have high multiples and higher growth rates, others have lower multiples and lower growth rates. Here’s how I decided which one to choose.

The covid situation is always changing so it’s time to check in on this trade thesis.

IntelliHR (ASX:IHR) have damaged their own reputation by acting in a way that favours stockbrokers over its own retail shareholders.

One has director buying, the other has revenue growth well over 100%, but neither of them are much talked about by small cap fund managers (yet)…

The IntelliHR stock price has been on a wild ride ranging from 59c to 20c in the last year. In contrast its ARR is only increasing (strongly).

The Objective Corp FY2021 results were very strong but do they justify the 58% share price gain in the last year?

Unfortunately for shareholders, Damstra’s stretched balance sheet is overshadowing its high margin annualised recurring revenue.

These three companies report quarterly, but their Annual Reports still offer a valuable window into the company.